Kovina Therapeutics
Updated: January 31, 2026
CEO Kristin Sherman, Founder Elliot Androphy
Country: USA | Funding: $2.6M (+)
Founded: 2020
Website: https://www.kovina.com/
Kovina Therapeutics is a preclinical biotechnology company developing a unique antiviral drug for the treatment of cancer and precancerous conditions associated with the human papillomavirus (HPV), including cervical, anal and oropharyngeal cancers. The company used powerful biotechnological tools to study the molecular mechanisms by which HPV proteins control infected cells and discovered new therapeutic molecules that block viral activity. The developed therapy should provide a non-surgical treatment option for HPV-induced cancer and precancerous conditions. This small-molecule drug specifically targets the HPV E6 oncogene, an oncogenic factor expressed in both precancerous and cancerous tissues. By inactivating HPV E6, the drug triggers apoptosis in infected cells without affecting healthy tissue.
Founded: 2020
Website: https://www.kovina.com/
Kovina Therapeutics is a preclinical biotechnology company developing a unique antiviral drug for the treatment of cancer and precancerous conditions associated with the human papillomavirus (HPV), including cervical, anal and oropharyngeal cancers. The company used powerful biotechnological tools to study the molecular mechanisms by which HPV proteins control infected cells and discovered new therapeutic molecules that block viral activity. The developed therapy should provide a non-surgical treatment option for HPV-induced cancer and precancerous conditions. This small-molecule drug specifically targets the HPV E6 oncogene, an oncogenic factor expressed in both precancerous and cancerous tissues. By inactivating HPV E6, the drug triggers apoptosis in infected cells without affecting healthy tissue.
